Over the past 12 months, shares in Teva Pharmaceutical Industries (NYSE: TEVA) have rallied by around 108%. A key factor for Teva, one of the strongest-performing healthcare stocks, is its success in transforming itself primarily into a branded-drug company. This pivot has already started to manifest in Teva's earnings, with the company expected to report earnings per share (EPS) of $2.11 in 2026 and $3.09 in 2027. If the turnaround keeps unfolding, the stock could keep gaining, albeit at a slower pace than before. Image source: Getty Images.
CryptoAlerta — análise de criptomoedas e mercado em tempo real